Jackson Laboratory Joins Forces with New York Stem Cell Foundation to Revolutionize Biomedical Research
In a landmark acquisition, The Jackson Laboratory (JAX), a renowned leader in genetics and genomic medicine, has officially integrated the New York Stem Cell Foundation (NYSCF) into its operations. This strategic collaboration aims to transform the landscape of biomedical research and expedite the development of precision therapies for a wide array of diseases, including cancer, Alzheimer’s, diabetes, and more.
The confluence of JAX's extensive expertise in genetics and the innovative stem cell research capabilities of NYSCF creates one of the most formidable engines for biomedical discovery. By merging resources, both institutions are positioned at the forefront of utilizing cutting-edge technologies to facilitate early-stage research, enabling scientists to uncover disease mechanisms more efficiently.
This unification comes at a pivotal time when the integration of genetics, stem cell science, and artificial intelligence offers unprecedented opportunities to explore biological processes. As Lon Cardon, President and CEO of JAX, noted, this partnership represents a transformative moment in biomedical research. The synergy between genomics, stem cell innovation, and AI-driven research platforms provides scientists with robust tools for translating early insights into significant breakthroughs for patients.
Historically, JAX has garnered recognition for its work with genetically diverse mouse models, which are critical for understanding complex physiological processes. The introduction of NYSCF's advanced Global Stem Cell Array®, which features state-of-the-art automation technologies, will enhance the ability to conduct large-scale, reproducible stem cell research. This innovative approach allows for individual patient-level investigations, ultimately leading to more precise and effective treatment methodologies.
NYSCF, founded in 2005, has been at the forefront of developing scalable stem cell platforms that empower researchers globally to delve into disease studies, drug discovery, and regenerative medicine. By collaborating with JAX, renowned for its rigorous genetic research and leadership in NIH-funded initiatives, the merged entity aims to provide the biomedical community with enhanced tools for modeling human health and testing various interventions.
Daniel Paull, who is now JAX's Vice President of Discovery and Platform Development, highlighted the urgency behind NYSCF's mission to expedite cures to patients. The collaboration with JAX enhances that scientific urgency by leveraging a more powerful scientific engine, fostering a scenario where discoveries can be advanced sooner and with greater precision. This is particularly crucial in minimizing the costly failures that often impede later-stage clinical trials.
The practical implications of this union are profound. Induced pluripotent stem cells can transform into any cell type within the body, such as neurons to study neurological conditions like Alzheimer’s or cardiac cells to investigate heart diseases. With JAX's expertise in mouse genetics complemented by NYSCF's automated systems, researchers are granted a groundbreaking platform. This will enable them to predict therapeutic responses across diverse populations and validate findings through comprehensive studies in whole organisms, pushing the boundaries of precision medicine.
Both organizations will continue to operate independently while expanding their unified research capacities. NYSCF will maintain its headquarters in New York, while JAX will leverage its established international networks, enhancing research campuses across various locations including Maine, Connecticut, California, Florida, and Japan. Together, they are not just building a powerful research platform but are setting new standards for collaborative, scalable, and human-relevant biomedical research.
The Jackson Laboratory remains steadfast in its mission to discover precise genomic solutions to combat diseases and to empower the global biomedical community in the shared endeavor to better human health. Founded in Bar Harbor, Maine, in 1929, JAX has evolved into a global institution with nearly 3,000 employees and research facilities around the world. For more information about their ongoing efforts and groundbreaking research, visit www.jax.org.
The confluence of JAX's extensive expertise in genetics and the innovative stem cell research capabilities of NYSCF creates one of the most formidable engines for biomedical discovery. By merging resources, both institutions are positioned at the forefront of utilizing cutting-edge technologies to facilitate early-stage research, enabling scientists to uncover disease mechanisms more efficiently.
This unification comes at a pivotal time when the integration of genetics, stem cell science, and artificial intelligence offers unprecedented opportunities to explore biological processes. As Lon Cardon, President and CEO of JAX, noted, this partnership represents a transformative moment in biomedical research. The synergy between genomics, stem cell innovation, and AI-driven research platforms provides scientists with robust tools for translating early insights into significant breakthroughs for patients.
Historically, JAX has garnered recognition for its work with genetically diverse mouse models, which are critical for understanding complex physiological processes. The introduction of NYSCF's advanced Global Stem Cell Array®, which features state-of-the-art automation technologies, will enhance the ability to conduct large-scale, reproducible stem cell research. This innovative approach allows for individual patient-level investigations, ultimately leading to more precise and effective treatment methodologies.
NYSCF, founded in 2005, has been at the forefront of developing scalable stem cell platforms that empower researchers globally to delve into disease studies, drug discovery, and regenerative medicine. By collaborating with JAX, renowned for its rigorous genetic research and leadership in NIH-funded initiatives, the merged entity aims to provide the biomedical community with enhanced tools for modeling human health and testing various interventions.
Daniel Paull, who is now JAX's Vice President of Discovery and Platform Development, highlighted the urgency behind NYSCF's mission to expedite cures to patients. The collaboration with JAX enhances that scientific urgency by leveraging a more powerful scientific engine, fostering a scenario where discoveries can be advanced sooner and with greater precision. This is particularly crucial in minimizing the costly failures that often impede later-stage clinical trials.
The practical implications of this union are profound. Induced pluripotent stem cells can transform into any cell type within the body, such as neurons to study neurological conditions like Alzheimer’s or cardiac cells to investigate heart diseases. With JAX's expertise in mouse genetics complemented by NYSCF's automated systems, researchers are granted a groundbreaking platform. This will enable them to predict therapeutic responses across diverse populations and validate findings through comprehensive studies in whole organisms, pushing the boundaries of precision medicine.
Both organizations will continue to operate independently while expanding their unified research capacities. NYSCF will maintain its headquarters in New York, while JAX will leverage its established international networks, enhancing research campuses across various locations including Maine, Connecticut, California, Florida, and Japan. Together, they are not just building a powerful research platform but are setting new standards for collaborative, scalable, and human-relevant biomedical research.
The Jackson Laboratory remains steadfast in its mission to discover precise genomic solutions to combat diseases and to empower the global biomedical community in the shared endeavor to better human health. Founded in Bar Harbor, Maine, in 1929, JAX has evolved into a global institution with nearly 3,000 employees and research facilities around the world. For more information about their ongoing efforts and groundbreaking research, visit www.jax.org.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.